Clinical Trial Update: A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating escalating doses of ASP1235 (AGS62P1) as monotherapy in subjects with acute myeloid leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• ASP1235 (AGS62P1)

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: TERMINATED